SINGAPORE – June 6, 2014 –BD (Becton, Dickinson and Company), a leading global medical technology company, has announced through its Singapore-based subsidiary, Becton
Dickinson Holdings Pte Ltd, the signing of a distribution agreement with AITbiotech Pte Ltd, a leading manufacturer of molecular diagnostic (MDx) assays and provider of genomic services
based in Singapore, for the distribution of AITbiotech abTESTM BM qPCR assays in the Asia Pacific region.
“Our agreement with AITbiotech represents a key milestone in BD’s strategy to make the BD MAX™ System an indispensable laboratory tool that empowers laboratory professionals to provide rapid and accurate test results,” said Glen Costin, Business Director Molecular & Cancer Diagnostics Asia Pacific, BD Diagnostics. “The fully automated BD MAX™ System has a content-rich menu with a flexible open mode capability and standardized workflows that enable laboratories to consolidate a broad range of molecular tests that meet both their current and future needs.”
AITbiotech abTES™ BM assays are developed to optimize applications on the BD MAX™ System. The abTESTM BM assays are manufactured at AITbiotech’s ISO13485 certified facilities in Singapore. At present, abTES™ BM Research Use Only assays are available for detection of Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG), Herpes Simplex Virus 1/Herpes Simplex Virus 2/Varicella Zoster Virus (HSV1/2/VZV) and Mycobacterium tuberculosis (MTB).
"We are extremely excited about the opportunity to work with a leading global MDx company like BD,” said Alex Thian, AITbiotech CEO. “AITbiotech, sees the opportunity to work with BD and its unique fully automated BD MAX™ System as a great way to expand our assay offering.”